Tata Institute develops Rs 100 tablet to prevent cancer recurrence
text_fields
In a significant breakthrough, the Tata Institute in Mumbai claimed to have developed a groundbreaking treatment that could prevent the recurrence of cancer.
The researchers at the Tata Memorial Centre (TMC) worked diligently for ten years to create a tablet, that they assert could not only deter the return of cancer but also reduce the side effects of treatments like radiation and chemotherapy by 50%.
Dr. Rajendra Badve, a senior cancer surgeon at Tata Memorial Hospital and part of the research group, explained the process behind the discovery. He stated, "Human cancer cells were inserted into rats, forming tumors. The rats underwent radiation therapy, chemotherapy, and surgery. It was observed that dying cancer cells release chromatin particles, which, when entering healthy cells, can turn them cancerous."
The researchers found a solution to this problem by administering pro-oxidant tablets with resveratrol and copper (R+Cu) to the rats.
Dr. Badve elaborated, "The R+Cu tablets generate oxygen radicals that destroy chromatin particles. When taken orally, they generate oxygen radicals in the stomach, absorbed quickly into the bloodstream. These radicals destroy chromatin particles in circulation, preventing metastases — the movement of cancer cells from one part of the body to another. The tablet also prevents chemotherapy toxicity."
Referred to as the "Magic of R+Cu" in their presentation, the tablet is anticipated to substantially decrease the side effects of cancer treatment therapy by about 50% and demonstrate approximately 30% effectiveness in preventing cancer recurrence. The researchers claim its efficacy on various cancers, including those affecting the pancreas, lungs, and oral regions.
"After nearly a decade of dedicated work by Tata doctors, the tablet is pending approval from the Food Safety and Standards Authority of India (FSSAI). TIFR scientists have applied for approval, and once granted, the tablet is expected to hit the market by June-July. This affordable tablet, priced at just Rs 100, is poised to revolutionize cancer treatment," highlighted Dr. Badve.
While human trials for prevention are still pending and expected to take around five years to complete, the positive impact on side effects has been tested on both rats and humans. Dr. Badve acknowledged the initial skepticism during the research process but emphasized the immense success achieved, stating, "It is a big success."
